New shot for high cholesterol passes first safety test in humans

NCT ID NCT06541457

Completed Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a single injection of HRS-7249 in 48 healthy adults with high cholesterol. The main goal was to check safety and how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo, and researchers monitored for side effects. This is a first step to see if the drug might one day help control cholesterol levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7249 injection
What this could lead to: If successful, this could lead to a new injectable treatment for high cholesterol, offering a convenient alternative to daily pills.
What could go wrong: This is an early Phase 1 trial with only 48 healthy people, so it is too soon to know if it works or is safe. The drug may cause side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPIDEMIA

Contacts and locations

Locations

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.